An alternative way - tyrosine kinase inhibitor (TKI) de-escalation - to discontinue TKIs in order to achieve treatment-free remission
- Resource Type
- Authors
- Ahmet Emre Eskazan; Ahmad Kunbaz
- Source
- Expert review of hematology. 12(7)
- Subject
- medicine.drug_class
Remission, Spontaneous
Antineoplastic Agents
Malignancy
Tyrosine-kinase inhibitor
Remission induction
Myelogenous
hemic and lymphatic diseases
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
medicine
Humans
Molecular Targeted Therapy
neoplasms
Protein Kinase Inhibitors
business.industry
Remission Induction
Myeloid leukemia
Imatinib
Hematology
medicine.disease
respiratory tract diseases
Leukemia
Cancer research
business
De-escalation
medicine.drug
- Language
- ISSN
- 1747-4094
Since the introduction of imatinib ‘the first tyrosine kinase inhibitor (TKI)’ that targets BCR-ABL1, chronic myeloid leukemia (CML) has become a controlled malignancy at which patients with optima...